ALKS Quote, Financials, Valuation and Earnings

Avadel Pharmaceuticals PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -9.37%. Alkermes PLC's return on equity of 25.91% beat Avadel Pharmaceuticals PLC's return on equity of -35.57%.

Alkermes PLC has a consensus price target of $39.93, signalling upside risk potential of 25.93%. On the other hand Avadel Pharmaceuticals PLC has an analysts' consensus of $17.00 which suggests that it could grow by 74.9%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.442, which suggesting that the stock is 55.775% less volatile than S&P 500. In comparison Avadel Pharmaceuticals PLC has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.879%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Avadel Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $306.5M, which are larger than Avadel Pharmaceuticals PLC quarterly revenues of $52.5M. Alkermes PLC's net income of $22.5M is higher than Avadel Pharmaceuticals PLC's net income of -$4.9M. Notably, Alkermes PLC's price-to-earnings ratio is 15.17x while Avadel Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.52x versus 4.82x for Avadel Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -10.31%. Alkermes PLC's return on equity of 25.91% beat Jazz Pharmaceuticals PLC's return on equity of 12.12%.

Alkermes PLC has a consensus price target of $39.93, signalling upside risk potential of 25.93%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $188.63 which suggests that it could grow by 69.73%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.442, which suggesting that the stock is 55.775% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.327, suggesting its less volatile than the S&P 500 by 67.347%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $306.5M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $897.8M. Alkermes PLC's net income of $22.5M is higher than Jazz Pharmaceuticals PLC's net income of -$92.5M. Notably, Alkermes PLC's price-to-earnings ratio is 15.17x while Jazz Pharmaceuticals PLC's PE ratio is 14.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.52x versus 1.74x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of 11.84%. Alkermes PLC's return on equity of 25.91% beat Medtronic PLC's return on equity of 9.51%.

Alkermes PLC has a consensus price target of $39.93, signalling upside risk potential of 25.93%. On the other hand Medtronic PLC has an analysts' consensus of $95.43 which suggests that it could grow by 9.14%. Given that Alkermes PLC has higher upside potential than Medtronic PLC, analysts believe Alkermes PLC is more attractive than Medtronic PLC.

Alkermes PLC has a beta of 0.442, which suggesting that the stock is 55.775% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.747%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.2% to investors and pays a quarterly dividend of $0.70 per share. Alkermes PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 76.98% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alkermes PLC quarterly revenues are $306.5M, which are smaller than Medtronic PLC quarterly revenues of $8.9B. Alkermes PLC's net income of $22.5M is lower than Medtronic PLC's net income of $1.1B. Notably, Alkermes PLC's price-to-earnings ratio is 15.17x while Medtronic PLC's PE ratio is 24.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.52x versus 3.36x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -0.61%. Alkermes PLC's return on equity of 25.91% beat Perrigo Co PLC's return on equity of -4.01%.

Alkermes PLC has a consensus price target of $39.93, signalling upside risk potential of 25.93%. On the other hand Perrigo Co PLC has an analysts' consensus of $36.50 which suggests that it could grow by 39.53%. Given that Perrigo Co PLC has higher upside potential than Alkermes PLC, analysts believe Perrigo Co PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.442, which suggesting that the stock is 55.775% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.43%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.33% to investors and pays a quarterly dividend of $0.29 per share. Alkermes PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.

Alkermes PLC quarterly revenues are $306.5M, which are smaller than Perrigo Co PLC quarterly revenues of $1B. Alkermes PLC's net income of $22.5M is higher than Perrigo Co PLC's net income of -$6.4M. Notably, Alkermes PLC's price-to-earnings ratio is 15.17x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.52x versus 0.83x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.